Fig. 2From: Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I studyThe Kaplan-Meier curves of patients received a dose of 60, 200 or 400 mg of camrelizumab. A Progression-free survival; B Overall survival (two-sided log-rank test)Back to article page